Status:
TERMINATED
Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia
Lead Sponsor:
AbbVie
Conditions:
Presbyopia
Eligibility:
All Genders
40-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AGN-241622 ophthalmic solution for the first time in human participants
Eligibility Criteria
Inclusion
- Age 40 to 65 at the time of study participation.
- Be a nonsmoker and nonuser of nicotine-containing products within the previous 1 year.
- Be able and willing to follow study instructions and complete all required study visits in the opinion of the study doctor.
Exclusion
- History of alcohol or substance abuse within the 5 years prior to study participation.
- Enrollment in another investigational drug or device study within 30 days of study participation.
- Women who are pregnant, nursing, or planning a pregnancy during the study.
Key Trial Info
Start Date :
July 27 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 5 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04403763
Start Date
July 27 2020
End Date
December 5 2022
Last Update
February 6 2024
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
United Medical Research Institute /ID# 234612
Inglewood, California, United States, 90301
2
Global Research Foundation /ID# 237353
Los Angeles, California, United States, 90041-1718
3
North Valley Eye Medical Group, Inc. /ID# 236686
Mission Hills, California, United States, 91345-1200
4
The Eye Research Foundation /ID# 234526
Newport Beach, California, United States, 92663-3637